Christopher O’Brien

2.4k total citations
45 papers, 1.5k citations indexed

About

Christopher O’Brien is a scholar working on Neurology, Psychiatry and Mental health and Cellular and Molecular Neuroscience. According to data from OpenAlex, Christopher O’Brien has authored 45 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Neurology, 20 papers in Psychiatry and Mental health and 10 papers in Cellular and Molecular Neuroscience. Recurrent topics in Christopher O’Brien's work include Neurological disorders and treatments (13 papers), Parkinson's Disease Mechanisms and Treatments (13 papers) and Botulinum Toxin and Related Neurological Disorders (12 papers). Christopher O’Brien is often cited by papers focused on Neurological disorders and treatments (13 papers), Parkinson's Disease Mechanisms and Treatments (13 papers) and Botulinum Toxin and Related Neurological Disorders (12 papers). Christopher O’Brien collaborates with scholars based in United States, Canada and United Kingdom. Christopher O’Brien's co-authors include Stewart A. Factor, Lauren Seeberger, Robert A. Hauser, Roland Jimenez, Joshua Burke, Grace Liang, Eric Molho, Jeffrey Friedlander, Charles H. Adler and Theresa Zesiewicz and has published in prestigious journals such as American Journal of Psychiatry, The Journal of Clinical Endocrinology & Metabolism and Neurology.

In The Last Decade

Christopher O’Brien

43 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher O’Brien United States 21 1.1k 449 346 129 126 45 1.5k
Sotirios A. Parashos United States 22 848 0.8× 313 0.7× 315 0.9× 131 1.0× 148 1.2× 42 1.3k
Peter Valkovič Slovakia 20 786 0.7× 255 0.6× 160 0.5× 104 0.8× 131 1.0× 78 1.3k
Davide Ferrazzoli Italy 21 992 0.9× 369 0.8× 108 0.3× 172 1.3× 98 0.8× 59 1.4k
Carlo Serrati Italy 25 829 0.8× 275 0.6× 382 1.1× 257 2.0× 150 1.2× 59 1.7k
Annachiara Cagnin Italy 17 415 0.4× 258 0.6× 246 0.7× 189 1.5× 218 1.7× 59 1.4k
Lydia Vela Spain 24 1.3k 1.3× 380 0.8× 315 0.9× 177 1.4× 91 0.7× 85 2.0k
Maja Relja Croatia 19 752 0.7× 305 0.7× 325 0.9× 94 0.7× 211 1.7× 41 1.3k
Jolyon Meara United Kingdom 15 776 0.7× 239 0.5× 156 0.5× 166 1.3× 41 0.3× 27 1.1k
Elisa Bianchi Italy 22 231 0.2× 580 1.3× 143 0.4× 79 0.6× 71 0.6× 91 1.2k
Juan Carlos Martínez‐Castrillo Spain 20 1.7k 1.6× 338 0.8× 261 0.8× 272 2.1× 68 0.5× 108 2.1k

Countries citing papers authored by Christopher O’Brien

Since Specialization
Citations

This map shows the geographic impact of Christopher O’Brien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher O’Brien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher O’Brien more than expected).

Fields of papers citing papers by Christopher O’Brien

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher O’Brien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher O’Brien. The network helps show where Christopher O’Brien may publish in the future.

Co-authorship network of co-authors of Christopher O’Brien

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher O’Brien. A scholar is included among the top collaborators of Christopher O’Brien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher O’Brien. Christopher O’Brien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Josiassen, Richard C., John M. Kane, Grace Liang, Joshua Burke, & Christopher O’Brien. (2025). Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder. Psychopharmacology Bulletin. 47(3). 61–68. 1 indexed citations
3.
Correll, Christoph U., Richard C. Josiassen, Grace Liang, Joshua Burke, & Christopher O’Brien. (2025). Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder. Psychopharmacology Bulletin. 47(3). 53–60.
4.
Kane, John M., Christoph U. Correll, Grace Liang, Joshua Burke, & Christopher O’Brien. (2025). Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder. Psychopharmacology Bulletin. 47(3). 69–76. 1 indexed citations
5.
Khan, Aliya, Riemer H. J. A. Slart, Oliver Bock, et al.. (2024). Osteoporotic Fractures: Diagnosis, Evaluation, and Significance From the International Working Group on DXA Best Practices. Mayo Clinic Proceedings. 99(7). 1127–1141. 18 indexed citations
6.
Huefner, Jonathan C., Christopher O’Brien, & Dennis G. Vollmer. (2021). Designing and Testing a Developmentally Appropriate Intervention for Children in a Psychiatric Residential Treatment Facility. Child and Adolescent Psychiatric Clinics of North America. 30(3). 527–536. 4 indexed citations
7.
Wyrwich, Kathleen W., Christopher O’Brien, Ahmed M. Soliman, & Kristof Chwalisż. (2018). Development and Validation of the Endometriosis Daily Pain Impact Diary Items to Assess Dysmenorrhea and Nonmenstrual Pelvic Pain. Reproductive Sciences. 25(11). 1567–1576. 19 indexed citations
8.
Factor, Stewart A., Cynthia L. Comella, Christoph U. Correll, et al.. (2017). Efficacy of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia: Results of a Long-Term Study (KINECT 3 Extension) (S56.005). Neurology. 88(16_supplement). 3 indexed citations
9.
O’Brien, Christopher, et al.. (2017). Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials. Drug Safety. 41(4). 429–440. 12 indexed citations
10.
Factor, Stewart A., Gary Remington, Cynthia Comella, et al.. (2017). The Effects of Valbenazine in Participants with Tardive Dyskinesia. The Journal of Clinical Psychiatry. 78(9). 1344–1350. 65 indexed citations
11.
Turcu, Adina F., Joanna L. Spencer-Segal, Robert Farber, et al.. (2016). Single-Dose Study of a Corticotropin-Releasing Factor Receptor-1 Antagonist in Women With 21-Hydroxylase Deficiency. The Journal of Clinical Endocrinology & Metabolism. 101(3). 1174–1180. 33 indexed citations
12.
Bari, Mohammed Abdul, et al.. (2016). Open-Label Extension of KINECT: A Phase 2 Study of Valbenazine (NBI-98854) for Tardive Dyskinesia (S27.001). Neurology. 86(16_supplement). 5 indexed citations
13.
Shephard, Mark, et al.. (2015). Review of the cultural safety of a national Indigenous point-of-care testing program for diabetes management. Australian Journal of Primary Health. 22(4). 368–368. 10 indexed citations
14.
O’Brien, Christopher, Allison Brashear, Paul A. Cullis, et al.. (2001). Cervical dystonia severity scale reliability study. Movement Disorders. 16(6). 1086–1090. 31 indexed citations
15.
Frucht, Steven J., Stanley Fahn, Paul Greene, et al.. (2001). The natural history of embouchure dystonia. Movement Disorders. 16(5). 899–906. 105 indexed citations
16.
Trosch, Richard, Joseph H. Friedman, Rajesh Pahwa, et al.. (1998). Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience. Movement Disorders. 13(3). 377–382. 97 indexed citations
17.
18.
Gormley, Mark, Christopher O’Brien, & Stuart A. Yablon. (1997). A clinical overview of treatment decisions in the management of spasticity. Muscle & Nerve. 20(S6). 14–20. 2 indexed citations
19.
O’Brien, Christopher. (1995). Involuntary Movement Disorders Following Lightning and Electrical Injuries. Seminars in Neurology. 15(3). 263–267. 22 indexed citations
20.
Richfield, Eric K., Christopher O’Brien, Thomas A. Eskin, & Ira Shoulson. (1991). Heterogeneous dopamine receptor changes in early and late Huntington's disease. Neuroscience Letters. 132(1). 121–126. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sotirios A. Parashos Breakdown of academic impact, for papers by Peter Valkovič Breakdown of academic impact, for papers by Davide Ferrazzoli Breakdown of academic impact, for papers by Carlo Serrati Breakdown of academic impact, for papers by Annachiara Cagnin Breakdown of academic impact, for papers by Lydia Vela Breakdown of academic impact, for papers by Maja Relja Breakdown of academic impact, for papers by Jolyon Meara Breakdown of academic impact, for papers by Elisa Bianchi Breakdown of academic impact, for papers by Juan Carlos Martínez‐Castrillo
Rankless by CCL
2026